TORONTO, Ontario and HAIFA, Israel, May 14, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, is pleased to announce that it has been selected to advance to Stage 2 of the EIT Health Catapult Programme 2026, a European Union-backed programme for high-potential companies addressing major healthcare priorities.
The Catapult Programme supports health innovation companies through expert training, investor exposure, and competitive pitch opportunities. NurExone was selected based on positive feedback from the programme’s reviewers regarding its strong and differentiated regenerative medicine platform, compelling preclinical data and meaningful regulatory progress.